StockMarketWire.com - Tiziana Life Sciences said a recently published study provided clinical evidence for the use of a treatment in the prevention of type-one diabetes.
The study was published in the New England Journal of Medicine and focused on the abilities of anti-CD3 antibody, Teplizumab.
Tiziana's own Foralumab offers potential safety and efficacy advantages over other anti-CD3 mAb's because it is the only fully human anti-CD3 mAb, as compared to mouse derived anti-CD3s which have been shown to cause immune reactions in humans, the company said.
Foralumab was currently in a Phase 1 trial at the Harvard Medical School in healthy volunteers to study safety, tolerability and biomarkers of neurodegenerative disease through nasal delivery.
An upcoming Phase 1 trial will evaluate oral Foralumab's safety, tolerability and biomarkers in Crohn's disease and NASH.
A Phase 2 trial in Crohn's and NASH is expected to commence next year.
At 9:59am: [LON:TILS] Tiziana Life Sciences Plc share price was +6p at 69p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.